INNOCOLL Company Profile
✉ Email this page to a colleague
What is the competitive landscape for INNOCOLL, and when can generic versions of INNOCOLL drugs launch?
INNOCOLL has two approved drugs.
There are eight US patents protecting INNOCOLL drugs.
There are one hundred and three patent family members on INNOCOLL drugs in thirty-three countries.
Summary for INNOCOLL
| International Patents: | 103 |
| US Patents: | 8 |
| Tradenames: | 2 |
| Ingredients: | 2 |
| NDAs: | 2 |
Drugs and US Patents for INNOCOLL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Innocoll | POSIMIR | bupivacaine | SOLUTION;INFILTRATION | 204803-001 | Feb 1, 2021 | RX | Yes | Yes | 11,400,019 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Innocoll | POSIMIR | bupivacaine | SOLUTION;INFILTRATION | 204803-001 | Feb 1, 2021 | RX | Yes | Yes | 8,846,072 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Innocoll Pharms | XARACOLL | bupivacaine hydrochloride | IMPLANT;IMPLANTATION | 209511-001 | Aug 28, 2020 | RX | Yes | Yes | RE47826 | ⤷ Subscribe | ⤷ Subscribe | ||||
| Innocoll | POSIMIR | bupivacaine | SOLUTION;INFILTRATION | 204803-001 | Feb 1, 2021 | RX | Yes | Yes | 11,771,624 | ⤷ Subscribe | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for INNOCOLL Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Eurasian Patent Organization | 201001885 | ⤷ Subscribe |
| Portugal | 2802624 | ⤷ Subscribe |
| Japan | 2010522738 | ⤷ Subscribe |
| Japan | 6720279 | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
